Compare MLGO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | CVM |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 32.4M |
| IPO Year | 2020 | 1996 |
| Metric | MLGO | CVM |
|---|---|---|
| Price | $4.06 | $4.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 180.4K | 38.9K |
| Earning Date | 04-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,132,230.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.91 | ★ N/A |
| Revenue Growth | 6.21 | ★ 65.45 |
| 52 Week Low | $0.50 | $0.23 |
| 52 Week High | $21.18 | $13.48 |
| Indicator | MLGO | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 62.80 |
| Support Level | $3.70 | $4.01 |
| Resistance Level | $4.73 | $4.73 |
| Average True Range (ATR) | 0.39 | 0.38 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 55.84 | 91.86 |
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.